posted on 2024-03-07, 11:29authored byJiali Li, Yan Wu, Qi Yuan, Luxin Li, Wenqi Qin, Jia Jia, Kaiyuan Chen, Dan Wu, Xiaohuan Yuan
Diabetic wound healing remains a worldwide challenge
for both clinicians
and researchers. The high expression of matrix metalloproteinase 9
(MMP9) and a high inflammatory response are indicative of poor diabetic
wound healing. H8, a curcumin analogue, is able to treat diabetes
and is anti-inflammatory, and our pretest showed that it has the potential
to treat diabetic wound healing. However, H8 is highly expressed in
organs such as the liver and kidney, resulting in its unfocused use
in diabetic wound targeting. (These data were not published, see Table
S1 in the Supporting Information.) Accordingly, it is important to
pursue effective carrier vehicles to facilitate the therapeutic uses
of H8. The use of H8 delivered by macrophage membrane-derived nanovesicles
provides a potential strategy for repairing diabetic wounds with improved
drug efficacy and fast healing. In this study, we fabricated an injectable
gelatin microsphere (GM) with sustained MMP9-responsive H8 macrophage
membrane-derived nanovesicles (H8NVs) with a targeted release to promote
angiogenesis that also reduces oxidative stress damage and inflammation,
promoting diabetic wound healing. Gelatin microspheres loaded with
H8NV (GMH8NV) stimulated by MMP9 can significantly facilitate the
migration of NIH-3T3 cells and facilitate the development of tubular
structures by HUVEC in vitro. In addition, our results
demonstrated that GMH8NV stimulated by MMP9 protected cells from oxidative
damage and polarized macrophages to the M2 phenotype, leading to an
inflammation inhibition. By stimulating angiogenesis and collagen
deposition, inhibiting inflammation, and reducing MMP9 expression,
GMH8NV accelerated wound healing. This study showed that GMH8NVs were
targeted to release H8NV after MMP9 stimulation, suggesting promising
potential in achieving satisfactory healing in diabetic treatment.